EXACT SCIENCES CORP Forms 3, 4 and 5: Restricted Stock Units and Performance Rights
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 53 rows in 2025. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2025-12-23: Reporting owner ORVILLE JACOB A; Form 4; Security Restricted Stock Units; Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2025-12-23: Reporting owner ORVILLE JACOB A; Form 4; Security Restricted Stock Units; Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2025-12-23: Reporting owner ORVILLE JACOB A; Form 4; Security Restricted Stock Units; Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2025-12-23: Reporting owner ORVILLE JACOB A; Form 4; Security Restricted Stock Units; Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2025-12-23 | ORVILLE JACOB A Officer (EVP, GM, Screening) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,955 0 owned after | $0.00 | 2025-12-30 | |
| 2025-12-23 | ORVILLE JACOB A Officer (EVP, GM, Screening) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −9,450 0 owned after | $0.00 | 2025-12-30 | |
| 2025-12-23 | ORVILLE JACOB A Officer (EVP, GM, Screening) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −14,845 0 owned after | $0.00 | 2025-12-30 | |
| 2025-12-23 | ORVILLE JACOB A Officer (EVP, GM, Screening) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −28,779 0 owned after | $0.00 | 2025-12-30 | |
| 2025-12-23 | ORVILLE JACOB A Officer (EVP, GM, Screening) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −16,051 0 owned after | $0.00 | 2025-12-30 | |
| 2025-12-23 | Baranick Brian Officer (EVP, GM, Precision Oncology) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,955 0 owned after | $0.00 | 2025-12-30 | |
| 2025-12-23 | Baranick Brian Officer (EVP, GM, Precision Oncology) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −9,450 0 owned after | $0.00 | 2025-12-30 | |
| 2025-12-23 | Baranick Brian Officer (EVP, GM, Precision Oncology) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −14,845 0 owned after | $0.00 | 2025-12-30 | |
| 2025-12-23 | Baranick Brian Officer (EVP, GM, Precision Oncology) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −28,779 0 owned after | $0.00 | 2025-12-30 | |
| 2025-12-23 | Baranick Brian Officer (EVP, GM, Precision Oncology) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −16,051 0 owned after | $0.00 | 2025-12-30 | |
| 2025-12-23 | Condella Sarah Officer (EVP, Human Resources) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,955 0 owned after | $0.00 | 2025-12-30 | |
| 2025-12-23 | Condella Sarah Officer (EVP, Human Resources) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,560 0 owned after | $0.00 | 2025-12-30 | |
| 2025-12-23 | Condella Sarah Officer (EVP, Human Resources) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −11,876 0 owned after | $0.00 | 2025-12-30 | |
| 2025-12-23 | Condella Sarah Officer (EVP, Human Resources) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −23,817 0 owned after | $0.00 | 2025-12-30 | |
| 2025-12-23 | Herriott James Officer (SVP, General Counsel & Sec) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,648 0 owned after | $0.00 | 2025-12-30 | |
| 2025-12-23 | Herriott James Officer (SVP, General Counsel & Sec) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,780 0 owned after | $0.00 | 2025-12-30 | |
| 2025-12-23 | Herriott James Officer (SVP, General Counsel & Sec) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,125 0 owned after | $0.00 | 2025-12-30 | |
| 2025-12-23 | Herriott James Officer (SVP, General Counsel & Sec) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −13,893 0 owned after | $0.00 | 2025-12-30 | |
| 2025-12-23 | Herriott James Officer (SVP, General Counsel & Sec) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,334 0 owned after | $0.00 | 2025-12-30 | |
| 2025-12-23 | Bloomer Aaron Officer (EVP, Chief Financial Officer) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −38,715 0 owned after | $0.00 | 2025-12-30 | |
| 2025-12-23 | Bloomer Aaron Officer (EVP, Chief Financial Officer) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −24,384 4,395 owned after | $0.00 | 2025-12-30 | |
| 2025-08-05 | ORVILLE JACOB A Officer (EVP, GM, Screening) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,350 16,051 owned after | $0.00 | 2025-08-07 | |
| 2025-08-05 | Baranick Brian Officer (EVP, GM, Precision Oncology) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,350 16,051 owned after | $0.00 | 2025-08-07 | |
| 2025-05-06 | Herriott James Officer (SVP, General Counsel & Sec) | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,334 7,334 owned after | $0.00 | 2025-05-08 | |
| 2025-04-15 | Bloomer Aaron Officer (EVP, Chief Financial Officer) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −11,566 0 owned after | $0.00 | 2025-04-17 | |
| 2025-04-15 | Bloomer Aaron Officer (EVP, Chief Financial Officer) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −12,904 38,715 owned after | $0.00 | 2025-04-17 | |
| 2025-02-28 | Herriott James Officer (SVP, General Counsel & Sec) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,890 3,780 owned after | $0.00 | 2025-03-04 | |
| 2025-02-28 | Herriott James Officer (SVP, General Counsel & Sec) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,375 7,125 owned after | $0.00 | 2025-03-04 | |
| 2025-02-28 | Conroy Kevin T Director, Officer (President and CEO) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −18,143 36,286 owned after | $0.00 | 2025-03-04 | |
| 2025-02-28 | Conroy Kevin T Director, Officer (President and CEO) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −22,167 66,504 owned after | $0.00 | 2025-03-04 | |
| 2025-02-28 | Baranick Brian Officer (EVP, GM, Precision Oncology) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −4,725 9,450 owned after | $0.00 | 2025-03-04 | |
| 2025-02-28 | Baranick Brian Officer (EVP, GM, Precision Oncology) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −4,948 14,845 owned after | $0.00 | 2025-03-04 | |
| 2025-02-28 | ORVILLE JACOB A Officer (EVP, GM, Screening) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −4,725 9,450 owned after | $0.00 | 2025-03-04 | |
| 2025-02-28 | ORVILLE JACOB A Officer (EVP, GM, Screening) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −4,948 14,845 owned after | $0.00 | 2025-03-04 | |
| 2025-02-28 | Condella Sarah Officer (EVP, Human Resources) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,780 7,560 owned after | $0.00 | 2025-03-04 | |
| 2025-02-28 | Condella Sarah Officer (EVP, Human Resources) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,958 11,876 owned after | $0.00 | 2025-03-04 | |
| 2025-02-25 | Condella Sarah Officer (EVP, Human Resources) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,954 3,955 owned after | $0.00 | 2025-02-26 | |
| 2025-02-25 | Baranick Brian Officer (EVP, GM, Precision Oncology) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,954 3,955 owned after | $0.00 | 2025-02-26 | |
| 2025-02-25 | Herriott James Officer (SVP, General Counsel & Sec) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,647 1,648 owned after | $0.00 | 2025-02-26 | |
| 2025-02-25 | ORVILLE JACOB A Officer (EVP, GM, Screening) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,954 3,955 owned after | $0.00 | 2025-02-26 | |
| 2025-02-25 | Conroy Kevin T Director, Officer (President and CEO) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −13,180 13,181 owned after | $0.00 | 2025-02-26 | |
| 2025-02-24 | Condella Sarah Officer (EVP, Human Resources) | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +23,817 23,817 owned after | $0.00 | 2025-02-26 | |
| 2025-02-24 | Baranick Brian Officer (EVP, GM, Precision Oncology) | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +28,779 28,779 owned after | $0.00 | 2025-02-26 | |
| 2025-02-24 | Herriott James Officer (SVP, General Counsel & Sec) | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +13,893 13,893 owned after | $0.00 | 2025-02-26 | |
| 2025-02-24 | ORVILLE JACOB A Officer (EVP, GM, Screening) | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +28,779 28,779 owned after | $0.00 | 2025-02-26 | |
| 2025-02-24 | Bloomer Aaron Officer (EVP, Chief Financial Officer) | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +28,779 28,779 owned after | $0.00 | 2025-02-26 | |
| 2025-02-24 | Conroy Kevin T Director, Officer (President and CEO) | 4 | Restricted Stock Units Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +111,146 111,146 owned after | $0.00 | 2025-02-26 | |
| 2025-02-19 | Conroy Kevin T Director, Officer (President and CEO) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,374 0 owned after | $0.00 | 2025-02-21 | |
| 2025-02-19 | COWARD D SCOTT Director | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,248 0 owned after | $0.00 | 2025-02-21 | |
| 2025-02-19 | ORVILLE JACOB A Officer (EVP, GM, Screening) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,248 0 owned after | $0.00 | 2025-02-21 | |
| 2025-02-19 | Baranick Brian Officer (EVP, GM, Precision Oncology) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,729 0 owned after | $0.00 | 2025-02-21 | |
| 2025-02-19 | Condella Sarah Officer (EVP, Human Resources) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,248 0 owned after | $0.00 | 2025-02-21 | |
| 2025-02-19 | Herriott James Officer (SVP, General Counsel & Sec) | 4 | Restricted Stock Units Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −865 0 owned after | $0.00 | 2025-02-21 |